RNAi Therapeutics - How this New Class of Medicines Works

This video was created for U.S. audiences. Alnylam is the world’s leading RNA interference (RNAi) company and has pioneered the 2006 Nobel Prize-winning discovery of RNAi into an innovative new class of medicines. RNAi therapeutics work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. In doing so, RNAi therapeutics work “upstream” of most other classes of medicines, such as small molecules and monoclonal antibodies, by targeting the “root” genetic cause of a disease rather than its symptoms. Since 2002, Alnylam has worked to pioneer RNAi-based medicines through sustained R&D efforts that have yielded the critical breakthroughs and innovations that make RNAi therapeutics possible. Alnylam’s RNAi therapeutics utilize specially designed small interfering RNAs (siRNAs) which disable another type of RNA called messenger RNA (mRNA), which is implicated in the pathway of disease. Learn more about our science: #RNAi #RNAitherapeutics #siRNA Corp-USA-00046